RADX Stock Summary and Trading Ideas (Radiopharm Theranostics Limited - American Depositary Shares | NASDAQ:RADX)

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Radiopharm Theranostics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol RADX.

As of March 2, 2026, RADX stock price declined to $4.95 with 47,556 million shares trading.

RADX has a beta of 0.10, meaning it tends to be less sensitive to market movements. RADX has a correlation of 0.00 to the broad based SPY ETF.

RADX has a market cap of $38.51 million. This is considered a Sub-Micro Cap stock.

RADX has underperformed the market in the last year with a return of -3.1%, while SPY returned +18.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RADX shares. However, RADX has outperformed the market in the last 3 month and 2 week periods, returning +6.7% and +1.0%, while SPY returned +1.3% and +0.7%, respectively. This indicates RADX has been having a stronger performance recently.

RADX support price is $4.78 and resistance is $5.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RADX shares will trade within this expected range on the day.